Delving into the Latest Updates on Elpiscience (Suzhou) Biopharma, Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Digestive System Disorders

Bispecific antibody

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Bispecific antibody	3
Monoclonal antibody	3

Top 5 Target	Count

4-1BB x PDL1	1
LAG3(Lymphocyte activation gene 3 protein)	1
SIRPα(Signal-regulatory protein alpha)	1
DLL4 x VEGF-A	1
CD39 x TGF-β	1

OVERALL DESIGN: This study is an open-label, single-center, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, and tolerability of ES014 in adults with advanced solid tumors. Adult patients with unresectable locally advanced or metastatic solid tumors will be enrolled in this study. This study is not blinded.
Subject type and number : The study population will be adults with unresectable locally advanced or metastatic solid tumors, whose disease has progressed despite standard therapy and for whom no further standard therapy exists; or for whom standard therapy has proven to be ineffective or intolerable.
This study is expected to enroll no more than 15 subjects, including malignant pleural mesothelioma and myxofibrosarcoma, 4-5, respectively, 2-3 malignant peripheral nerve sheath tumors, and other solid tumors.
Duration of treatment: Subjects will be treated with ES014 in 28-day cycles. ES014 will be administered at 1400 mg on days 1 and 15 of each cycle. Each subject will be treated with study drug for a maximum of 24 months. Subjects will be treated according to protocol until disease progression per RECIST v1.1, development of unacceptable toxicity, withdrawal of consent, completion of study treatment of 24 months, end of study, or early termination of study by sponsor, or other discontinuation and withdrawal reason, whichever occurs first.

Start Date20 Aug 2024

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

[+1]

CTR20230045 / RecruitingPhase 1

ES014用于局部晚期或转移性实体瘤患者的开放标签、多中心、剂量递增和队列扩展的I期临床研究

[Translation] An open-label, multicenter, dose-escalation, and cohort expansion Phase I clinical study of ES014 in patients with locally advanced or metastatic solid tumors

这是一项开放标签的多中心研究，旨在研究ES014在经标准治疗后疾病进展或不适合标准治疗的晚期实体瘤患者中的安全性、耐受性、药代动力学（PK）、药效学和初步临床活性。确定ES014的最大耐受剂量（MTD）/最大给药剂量（MAD）、最佳生物效应剂量（OBD）和推荐II期剂量（RP2D）。

[Translation]

This is an open-label, multicenter study designed to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary clinical activity of ES014 in patients with advanced solid tumors who have progressed after standard therapy or are not suitable for standard therapy. The maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological effect dose (OBD), and recommended phase II dose (RP2D) of ES014 were determined.

Start Date21 Feb 2023

Sponsor / Collaborator

Elpiscience (Suzhou) Biopharma, Ltd.

100 Clinical Results associated with Elpiscience (Suzhou) Biopharma, Ltd.

Login to view more data

0 Patents (Medical) associated with Elpiscience (Suzhou) Biopharma, Ltd.

Login to view more data

1

News (Medical) associated with Elpiscience (Suzhou) Biopharma, Ltd.

04 Jan 2023

·www.biospace.com

Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)-- Elpiscience Biopharma, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P. Morgan Week 2023 in San Francisco in January. Elpiscience’s Co-Founder and CEO Darren Ji will also be sharing his perspective on the BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities panel at the conference. “We are excited to bring to the world our novel immunotherapies, including our first-in-class anti-CD39/TGF-β bispecific antibody ES014 potentially for PD-(L)1 resistant patient population, a highly differentiated anti-LILRB2 antibody ES009, and a pan-acting anti-SIPRα antibody ES004. We look forward to collaborating with pharmaceutical partners to advance our innovative drug candidates to benefit cancer patients worldwide,” said Darren Ji, Co-Founder, and CEO of Elpiscience. Event Schedules: Elpiscience’s presentation Darren Ji, Co-Founder and CEO of Elpiscience Date and Time: 9 January 2023, 14:30 – 14:45 PST Location: Hilton Union Square, Franciscan C (Ballroom Level), San Francisco CA Panel: BioPharma Business in the Asia Pacific Region: Huge Markets, Great Opportunities Darren Ji, Co-Founder and CEO of Elpiscience Date and Time: 10 January 2023, 9:00 – 10:00 PST Location: Hilton Union Square, Imperial Ballroom, San Francisco CA Elpiscience’s team is participating in partnering system and welcomes the opportunity to meet with potential partners. For meeting appointments, registered attendees can send a request through Biotech Showcase Partnering Platform, and or by contacting Elpiscience directly at BD@elpiscience.com. About Elpiscience Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide. The Company has a robust pipeline of globally innovative cancer immunotherapies covering a wide range of oncology targets and multiple proprietary technologies to enable discovery including its Bispecific Macrophage Engager (BiME®) antibody platform for solid tumors, human antibody Fab library ElpiSource™ and H-L interchain disulfide bond engineering BsAb platform Acebody™. Founded and managed by a team of biotechnology industry leaders and scientists, Elpiscience is supported by a world-class Scientific Advisory Board and high-quality investors including Lilly Asia Ventures, GL Ventures, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management. For more information, please visit .

Immunotherapy

100 Deals associated with Elpiscience (Suzhou) Biopharma, Ltd.

Login to view more data

100 Translational Medicine associated with Elpiscience (Suzhou) Biopharma, Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Approval

Phase 1

2

3

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ES-014 ( CD39 x TGF-β )	Advanced Malignant Solid Neoplasm More	Phase 2
TR-009 ( DLL4 x VEGF-A )	Metastatic Colorectal Carcinoma More	Phase 1/2
INBRX-106 ( OX40 )	Advanced Malignant Solid Neoplasm More	Phase 1
ES-004 ( SIRPα )	Solid tumor More	Phase 1
Eurestobart ( CD39 )	Solid tumor More	IND Approval